These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 7532717)
21. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Tokunaga M; Fujii K; Saito K; Nakayamada S; Tsujimura S; Nawata M; Tanaka Y Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350 [TBL] [Abstract][Full Text] [Related]
22. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Kumar S; Benseler SM; Kirby-Allen M; Silverman ED Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962 [TBL] [Abstract][Full Text] [Related]
23. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Leandro MJ; Cambridge G; Edwards JC; Ehrenstein MR; Isenberg DA Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950 [TBL] [Abstract][Full Text] [Related]
24. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284 [TBL] [Abstract][Full Text] [Related]
25. A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Davis JC; Austin H; Boumpas D; Fleisher TA; Yarboro C; Larson A; Balow J; Klippel JH; Scott D Arthritis Rheum; 1998 Feb; 41(2):335-43. PubMed ID: 9485092 [TBL] [Abstract][Full Text] [Related]
26. Peripheral blood CD5+ B cell subset in the remission phase of systemic connective tissue diseases. Markeljević J; Batinić D; Uzarević B; Bozikov J; Cikes N; Babić-Naglić D; Horvat Z; Marusić M J Rheumatol; 1994 Dec; 21(12):2225-30. PubMed ID: 7535356 [TBL] [Abstract][Full Text] [Related]
27. Expression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus. Yang JH; Zhang J; Cai Q; Zhao DB; Wang J; Guo PE; Liu L; Han XH; Shen Q Rheumatology (Oxford); 2005 Oct; 44(10):1245-54. PubMed ID: 15987711 [TBL] [Abstract][Full Text] [Related]
28. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Looney RJ; Anolik JH; Campbell D; Felgar RE; Young F; Arend LJ; Sloand JA; Rosenblatt J; Sanz I Arthritis Rheum; 2004 Aug; 50(8):2580-9. PubMed ID: 15334472 [TBL] [Abstract][Full Text] [Related]
30. Increased peripheral blood B-cells expressing the CD5 molecules in association to autoantibodies in patients with lupus erythematosus and evidence to selectively down-modulate them. Böhm I Biomed Pharmacother; 2004 Jun; 58(5):338-43. PubMed ID: 15194170 [TBL] [Abstract][Full Text] [Related]
31. The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins. Manske JM; Buchsbaum DJ; Vallera DA J Immunol; 1989 Mar; 142(5):1755-66. PubMed ID: 2465347 [TBL] [Abstract][Full Text] [Related]
32. Ex vivo depletion of human bone marrow T lymphocytes by soybean lectin fractionation followed by treatment with an anti-pan-T cell (CD5) ricin A- chain immunotoxin. Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM Transplant Proc; 1987 Feb; 19(1 Pt 3):2735-7. PubMed ID: 3274583 [No Abstract] [Full Text] [Related]
33. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458 [TBL] [Abstract][Full Text] [Related]
34. Simultaneous ligation of CD5 and CD28 on resting T lymphocytes induces T cell activation in the absence of T cell receptor/CD3 occupancy. Verwilghen J; Vandenberghe P; Wallays G; de Boer M; Anthony N; Panayi GS; Ceuppens JL J Immunol; 1993 Feb; 150(3):835-46. PubMed ID: 7678624 [TBL] [Abstract][Full Text] [Related]
35. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Leandro MJ; Cambridge G; Ehrenstein MR; Edwards JC Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239 [TBL] [Abstract][Full Text] [Related]
36. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609 [TBL] [Abstract][Full Text] [Related]
37. Investigation and prevention of artifactual staining in flow cytometric analyses of whole blood samples from patients treated with H65-RTA, an anti-CD5 monoclonal antibody conjugated to ricin A chain. Fishwild DM; Saria EA J Immunol Methods; 1991 Nov; 144(1):27-34. PubMed ID: 1720441 [TBL] [Abstract][Full Text] [Related]
38. Ganglioside GQ1b enhances anti-double-stranded DNA antibody and IgG production of PBMCs from patients with systemic lupus erythematosus. Kanda N; Watanabe S J Allergy Clin Immunol; 2000 Mar; 105(3):532-40. PubMed ID: 10719304 [TBL] [Abstract][Full Text] [Related]